Cargando…

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands

PURPOSE: A large number of targeted treatment options for stage IV nonsquamous non–small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is therefore important to optimize diagnostic testing strategies, such that patients receive adequate personalized treatment that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolff, Henri B., Steeghs, Elisabeth M.P., Mfumbilwa, Zakile A., Groen, Harry J.M., Adang, Eddy M., Willems, Stefan M., Grünberg, Katrien, Schuuring, Ed, Ligtenberg, Marjolijn J.L., Tops, Bastiaan B.J., Coupé, Veerle M.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307305/ https://www.ncbi.nlm.nih.gov/pubmed/35834758 http://dx.doi.org/10.1200/PO.22.00201

Ejemplares similares

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
por: Boleij, Annemarie, et al.
Publicado: (2015)

Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2021)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2020)

Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice
por: Steeghs, Elisabeth M P, et al.
Publicado: (2022)

Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations
por: Willemsen, Annelieke E. C. A. B., et al.
Publicado: (2019)

“The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology”: letter to the Editor
por: Dinjens, Winand N. M., et al.
Publicado: (2020)

Comprehensive molecular and clinicopathological analysis of vascular malformations: A study of 319 cases
por: Ten Broek, Roel W., et al.
Publicado: (2019)

The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment
por: Dijkstra, Jeroen R., et al.
Publicado: (2015)

Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?
por: Keppens, Cleo, et al.
Publicado: (2019)

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
por: Simons, Martijn J. H. G., et al.
Publicado: (2021)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

The cumulative false-positive rate in colorectal cancer screening: a Markov analysis
por: Haug, Ulrike, et al.
Publicado: (2020)

Improving calculation, interpretation and communication of familial colorectal cancer risk: Protocol for a randomized controlled trial
por: Dekker, Nicky, et al.
Publicado: (2010)

Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium
por: Tops, Bastiaan BJ, et al.
Publicado: (2015)

Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
por: Wolff, Henri B., et al.
Publicado: (2022)

Universal genetic assessment for women with ovarian cancer not yet achieved: The promises of universal tumor DNA testing
por: Witjes, Vera M., et al.
Publicado: (2021)

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
por: Deans, Zandra C, et al.
Publicado: (2016)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
por: Weren, Robbert D.A., et al.
Publicado: (2016)

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
por: van den Broek, Daan, et al.
Publicado: (2020)

Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
por: van den Heuvel, Guus R. M., et al.
Publicado: (2021)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Familial gastric cancer: detection of a hereditary cause helps to understand its etiology
por: Vogelaar, Ingrid P, et al.
Publicado: (2012)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Guidance for laboratories performing molecular pathology for cancer patients
por: Cree, Ian A, et al.
Publicado: (2014)

Cost-effectiveness of breast cancer screening using mammography in Vietnamese women
por: Nguyen, Chi Phuong, et al.
Publicado: (2018)

Cost-effectiveness of the SEN-concept: Specialized Emergency Nurses (SEN) treating ankle/foot injuries
por: Derksen, Robert J, et al.
Publicado: (2007)

The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
por: Stadhouders, Niek, et al.
Publicado: (2019)

Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics
por: Eijkelenboom, Astrid, et al.
Publicado: (2019)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

Response to Tomao, Panici, and Tomao
por: Vos, Janet R, et al.
Publicado: (2019)

Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients
por: Lassche, Gerben, et al.
Publicado: (2022)

Mismatch repair deficiency in early‐onset duodenal, ampullary, and pancreatic carcinomas is a strong indicator for a hereditary defect
por: Kryklyva, Valentyna, et al.
Publicado: (2021)

Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases
por: Hofste, Lisa S.M., et al.
Publicado: (2022)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial
por: Overbeek, L. I., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_sc7c63deg1cn8vk4ql3naeto7g